{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+Neuroendocrine+Neoplasms", "query": { "condition": "High Grade Neuroendocrine Neoplasms" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 58, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+Neuroendocrine+Neoplasms&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T07:08:34.940Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03517488", "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma" ], "interventions": [ { "name": "XmAb20717", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2018-07-10", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 17, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517488" }, { "nct_id": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma of the Bladder", "High Grade Neuroendocrine Tumors of the Urinary Tract" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 45, "start_date": "2024-06-13", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06228066" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" }, { "nct_id": "NCT05420636", "title": "Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Iadademstat", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-12-21", "completion_date": "2025-07-23", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 3, "location_summary": "Buffalo, New York • Philadelphia, Pennsylvania • Salt Lake City, Utah", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05420636" }, { "nct_id": "NCT06406465", "title": "A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Neuroendocrine", "Tumor, Neuroendocrine", "Tumors, Neuroendocrine", "Neuroendocrine; Carcinoma", "Small Cell; Receptors" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 60, "start_date": "2026-06-15", "completion_date": "2028-07-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06406465" }, { "nct_id": "NCT00002754", "title": "Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "monoclonal antibody Me1-14 F(ab')2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 6, "start_date": "1993-02", "completion_date": "2001-04", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002754" }, { "nct_id": "NCT04163419", "title": "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schwannomatosis", "Pain" ], "interventions": [ { "name": "Tanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-04-30", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04163419" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT03340506", "title": "Dabrafenib and/or Trametinib Rollover Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Melanoma", "Non Small Cell Lung Cancer", "Solid Tumor", "Rare Cancers", "High Grade Glioma" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 100, "start_date": "2017-12-28", "completion_date": "2032-12-28", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03340506" }, { "nct_id": "NCT03333616", "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genitourinary Cancer", "Adrenocortical Carcinoma", "Non-urothelial Bladder", "Non-urothelial Upper Tract", "Penile Cancer", "Non-adenocarcinoma Prostate Cancer", "Refractory Germ-cell", "High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2017-12-28", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-11T07:08:34.940Z", "location_count": 6, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333616" } ] }